We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VLP

News List

Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 03, 2021
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.
Allergy Therapeutics launches biomarker study of peanut allergy vaccine candidate pharmatimes
January 07, 2021
Allergy Therapeutics has initiated a biomarker study at Imperial College London, which will aim to evaluate its novel virus like particle (VLP) based peanut allergy vaccine candidate.
Premas Biotech initiates triple antigen VLP COVID-19 vaccine candidate for animal trials expresspharma
July 09, 2020
At the moment, it is the only one from India to adopt a triple-antigen approach that is designed to produce an enhanced immune response.
Premas Biotech announces completion of vaccine prototype of triple-antigen candidate against COVID-1 expresspharma
May 20, 2020
Reportedly, the vaccine prototype is among the first in the world for VLP of SARS CoV-2 virus.